Exelixis Inc., of South San Francisco, appointed George Poste to its board.

Genaissance Pharmaceuticals Inc., of New Haven, Conn., appointed Matthew Kalnik senior vice president of business development.

GeneMax Corp., of Vancouver, British Columbia, appointed Konstantine Sarafis chief operating officer.

Genetronics Biomedical Corp., of San Diego, appointed Riaz Bandali to its board.

GenoMed Inc., of St. Louis, named Dennis Robbins chairman of its business advisory board.

GlobeImmune Inc., of Aurora, Colo., appointed Ed Venkat director of process development; Aurelia Haller virology program leader; Carol Walker director of quality control; Aline Oliver associate director of quality assurance; and Grant Wiemers controller and director of finance.

GPC Biotech AG, of Martinsried, Germany, appointed James Frates to its supervisory board.

Haemonetics Corp., of Braintree, Mass., appointed Susan Bartlett Foote and Pedro Granadillo to its board.

Hemosol Corp., of Toronto, appointed Edward Lane to its board.

Immusol Inc., of San Diego, appointed Gerard Wills chief financial officer.

The Indiana Centers for Applied Protein Sciences in Indianapolis appointed Carl Bruhn chief business officer; Susan Montgomery office manager; and Jinsam You, Tony Tegeler and Dariusz Janecki to its scientific team. It also hired Ivan Jenkins, Jaime Smith, Kerry Bemis and Mu Wang.

Integrated Pharmaceuticals Inc., of Fitchburg, Mass., appointed Hermann Oppermann vice president of biologics development.

InterMune Inc., of Brisbane, Calif., appointed Tom Kassberg senior vice president of business development and corporate strategy; Robin Steele senior vice president, general counsel and corporate secretary; and Howard Simon senior vice president of human resources and associated general counsel.

Introgen Therapeutics Inc., of Austin, Texas, appointed Peter Hutt to its board.

Invitrogen Corp., of Carlsbad, Calif., appointed Ronald Matricaria to its board, and David Franz, Margaret Hamburg, Stephen Albert Johnston, Scott Lillibridge, C.J. Peters and Dennis Reimer to a biological defense systems advisory board.

NeoStem, of Agoura Hills, Calif., appointed Brad Maroni vice president of clinical development.

Savient Pharmaceuticals Inc., of East Brunswick, N.J., appointed Lawrence Gyenes senior vice president, chief financial officer and treasurer.

Transave Inc., of Monmouth Junction, N.J., appointed Jeffry Weers vice president of research and development, and Susan Nicholson vice president of medical affairs.

No Comments